Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Jul;94(3):745–754. doi: 10.1111/j.1476-5381.1988.tb11584.x

AH6809, a prostaglandin DP-receptor blocking drug on human platelets.

R J Keery 1, P Lumley 1
PMCID: PMC1854016  PMID: 2460179

Abstract

1. The effect of AH6809 (6-isopropoxy-9-oxoxanthene-2-carboxylic acid) has been studied upon the anti-aggregatory and aggregatory actions of various agents on human platelets in whole blood. 2. Prostaglandin D2 (PGD2), BW245C, 9 alpha, 11 beta-PGF2, PGI2 and 5'-N-ethylcarboxamide adenosine (NECA) all inhibited ADP-induced platelet aggregation in whole blood. The anti-aggregatory activity of PGD2, BW245C and 9 alpha, 11 beta-PGF2 but not PGI2 or NECA was antagonized by AH6809. NECA was antagonized by AH6809. 3. The antagonism of the anti-aggregatory activity of PGD2 by AH6809 was concentration-related and could be overcome by increasing the concentration of PGD2. Analysis of the data yielded an apparent pA2 for AH6809 of 5.35. 4. At approximately 10 fold higher concentrations than those required to antagonize the action of PGD2, AH6809 also antagonized the aggregatory effect of U-46619 in whole blood (pA2 = 4.45). However, concentrations of AH6809 up to 300 microM were without effect upon either ADP- or platelet activating factor (Paf)-induced aggregation (pA2 less than 3.5). 5. The potency of AH6809 against PGD2 and U-46619 was increased in a resuspended platelet preparation suggesting that the drug is extensively bound to plasma proteins. However, in resuspended platelets the specificity of AH6809 relative to that seen in whole blood was reduced since aggregation by ADP and Paf was also slightly antagonized. 6. In conclusion, AH6809 appears to be a weak but specific DP-receptor blocking drug on human platelets and should prove to be a useful drug tool for defining the involvement of endogenous PGD2 in platelet aggregation and classifying the mode of action of anti-aggregatory prostanoids.

Full text

PDF
745

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alvarez R., Taylor A., Fazzari J. J., Jacobs J. R. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins. Mol Pharmacol. 1981 Sep;20(2):302–309. [PubMed] [Google Scholar]
  3. Brittain R. T., Boutal L., Carter M. C., Coleman R. A., Collington E. W., Geisow H. P., Hallett P., Hornby E. J., Humphrey P. P., Jack D. AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation. 1985 Dec;72(6):1208–1218. doi: 10.1161/01.cir.72.6.1208. [DOI] [PubMed] [Google Scholar]
  4. Cooper B., Schafer A. I., Puchalsky D., Handin R. I. Desensitization of prostaglandin-activated platelet adenylate cyclase. Prostaglandins. 1979 Apr;17(4):561–571. doi: 10.1016/0090-6980(79)90007-8. [DOI] [PubMed] [Google Scholar]
  5. Eakins K. E., Rajadhyaksha V., Schroer R. Prostaglandin antagonism by sodium p-benzyl-4-[1-oxo-2-(4-chlorobenzyl)-3-phenylpropyl]pheenyl phosphonate (N-0164). Br J Pharmacol. 1976 Nov;58(3):333–339. doi: 10.1111/j.1476-5381.1976.tb07709.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Horne W. C. Desacetyl-1-nantradol: a selective prostaglandin antagonist. Prostaglandins Leukot Med. 1984 Jul;15(1):129–136. doi: 10.1016/0262-1746(84)90063-5. [DOI] [PubMed] [Google Scholar]
  7. Jones R. L. Definition of prostaglandin-sensitive arterial constrictor systems. Acta Biol Med Ger. 1978;37(5-6):837–844. [PubMed] [Google Scholar]
  8. Jones R. L., Wilson N. H. Prostaglandins D and F with highly selective agonist actions [proceedings]. Br J Pharmacol. 1977 Jun;60(2):315P–315P. [PMC free article] [PubMed] [Google Scholar]
  9. Kennedy I., Coleman R. A., Humphrey P. P., Levy G. P., Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 1982 Nov;24(5):667–689. doi: 10.1016/0090-6980(82)90036-3. [DOI] [PubMed] [Google Scholar]
  10. Kulkarni P. S., Eakins K. E. N-0164 inhibits generation of thromboxane-A2-like activity from prostaglandin endoperoxides by human platelet microsomes. Prostaglandins. 1976 Sep;12(3):465–469. doi: 10.1016/0090-6980(76)90027-7. [DOI] [PubMed] [Google Scholar]
  11. Liston T. E., Roberts L. J., 2nd Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6030–6034. doi: 10.1073/pnas.82.18.6030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lumley P., Humphrey P. P. A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods. 1981 Sep;6(2):153–166. doi: 10.1016/0160-5402(81)90038-3. [DOI] [PubMed] [Google Scholar]
  13. MacIntyre D. E., Gordon J. L. Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins. Thromb Res. 1977 Dec;11(6):705–713. doi: 10.1016/0049-3848(77)90099-8. [DOI] [PubMed] [Google Scholar]
  14. MacIntyre D. E., Salzman E. W. Antagonism of human platelet responses to stimulatory and inhibitory prostaglandins. Prog Lipid Res. 1981;20:453–459. doi: 10.1016/0163-7827(81)90081-3. [DOI] [PubMed] [Google Scholar]
  15. Miller O. V., Gorman R. R. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets. J Pharmacol Exp Ther. 1979 Jul;210(1):134–140. [PubMed] [Google Scholar]
  16. Mills D. C., Macfarlane D. E. Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb Res. 1974 Sep;5(3):401–412. doi: 10.1016/0049-3848(74)90176-5. [DOI] [PubMed] [Google Scholar]
  17. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  18. Narumiya S., Toda N. Different responsiveness of prostaglandin D2-sensitive systems to prostaglandin D2 and its analogues. Br J Pharmacol. 1985 Jun;85(2):367–375. doi: 10.1111/j.1476-5381.1985.tb08870.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sanner J. H. Antagonism of prostaglandin E2 by 1-acetyl-2-(8-chloro-10,11-dihydrodibenz (b,f) (1,4) oxazepine-10-carbonyl) hydrazine (SC-19220). Arch Int Pharmacodyn Ther. 1969 Jul;180(1):46–56. [PubMed] [Google Scholar]
  20. Schafer A. I., Cooper B., O'Hara D., Handin R. I. Identification of platelet receptors for prostaglandin I2 and D2. J Biol Chem. 1979 Apr 25;254(8):2914–2917. [PubMed] [Google Scholar]
  21. Siegl A. M., Smith J. B., Silver M. J. 3H-PGD2 binding by intact human platelets. Adv Prostaglandin Thromboxane Res. 1980;6:395–397. [PubMed] [Google Scholar]
  22. Siegl A. M., Smith J. B., Silver M. J. Specific binding sites for prostaglandin D2 on human platelets. Biochem Biophys Res Commun. 1979 Sep 12;90(1):291–296. doi: 10.1016/0006-291x(79)91623-1. [DOI] [PubMed] [Google Scholar]
  23. Smith J. B., Silver M. J., Ingerman C. M., Kocsis J. J. Prostaglandin D2 inhibits the aggregation of human platelets. Thromb Res. 1974 Sep;5(3):291–299. doi: 10.1016/0049-3848(74)90168-6. [DOI] [PubMed] [Google Scholar]
  24. Tateson J. E., Moncada S., Vane J. R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 1977 Mar;13(3):389–397. doi: 10.1016/0090-6980(77)90019-3. [DOI] [PubMed] [Google Scholar]
  25. Town M. H., Casals-Stenzel J., Schillinger E. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins. 1983 Jan;25(1):13–28. doi: 10.1016/0090-6980(83)90131-4. [DOI] [PubMed] [Google Scholar]
  26. Tynan S. S., Andersen N. H., Wills M. T., Harker L. A., Hanson S. R. On the multiplicity of platelet prostaglandin receptors. II. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogs. Prostaglandins. 1984 May;27(5):683–696. doi: 10.1016/0090-6980(84)90007-8. [DOI] [PubMed] [Google Scholar]
  27. Whittle B. J., Moncada S., Vane J. R. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978 Sep;16(3):373–388. doi: 10.1016/0090-6980(78)90216-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES